Investor Presentation First Nine Months of 2023
95
Investor presentation
First nine months of 2023
Novo NordiskⓇ
Large patient overlaps between diabetes, obesity, and CVD have
guided the focused approach in CVD
Population overlap between T2D, obesity and CVD
ILLUSTRATIVE
Focused approach in CVD
Atherosclerosis
Heart failure
ASCVD + HF
~425m
people
ASCVD
之仆
CRP
IL-6
Type 2 diabetes
~537m
people
Obesity
>764m
people
Ziltivekimab
Heart failure
fraction
with preserved ejection amyloid cardiomyopathy
Transthyretin
(ATTR-CM)
(HFPEF)
> > >
Treatments investigated
Semaglutide 2.4 mg
Ziltivekimab
PRX004
T2D: Type 2 diabetes, CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; HF: Heart failure; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein
Sources: IDF: Diabetes Atlas 10th edition, 2021, World Diabetes Atlas 2022View entire presentation